Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis.
Sign Up to like & getrecommendations! Published in 2017 at "Clinical immunology"
DOI: 10.1016/j.clim.2017.01.016
Abstract: Rheumatoid arthritis (RA) is a debilitating inflammatory autoimmune disease with no known cure. Recently, we identified the immunomodulatory enzyme indoleamine-2,3-dioxygenase 2 (IDO2) as an essential mediator of autoreactive B and T cell responses driving RA.… read more here.
Keywords: antibody; therapeutic antibody; dioxygenase ido2; indoleamine dioxygenase ... See more keywords